Skip to content

Inspection Record

Neurotech Pharmaceuticals, Inc. — FDA 483 Findings

US FDAInspected 2024-07-26Published 2026-10-26 3 findingsOther quality system

View the regulator's official source The source document is always the basis for judgement.

Findings

1Other quality system

The manual visual inspection program is inadequate to identify turbidity, precipitate, and particulates in the NT -501 combination product.

2Other quality system

Inadequate quality oversight to assure that the NT -501 combination product has the identity, strength, quality, and purity it purports or is represented to possess.

3Other quality system

Management with executive responsibility has not ensured that an adequate and effective quality system has been established.

A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Neurotech Pharmaceuticals, Inc. company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.